Cebiotex en la American Society of Clinical Oncology 2021

ASCO21: First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report.

You might also be interested in

Cebiotex successfully closes a crowdfunding round on Capital Cell

In only six weeks, Cebiotex’s crowdfunding round on Capital Cell

CEB-01 Phase-1 clinical trial progress presented at ESMO 2023